Dr. Guido Frank has spent more than 25 years treating anorexia nervosa patients, watching brilliant, determined people struggle against one of psychiatry's most lethal disorders—a condition that claims a life in the United States every 52 minutes. But a pilot study published today in Communications Medicine offers something he and his colleagues at UC San Diego School of Medicine have long sought: a genuinely new approach to a condition where effective treatments have remained stubbornly limited.
The research centers on a surprising intervention: a ketogenic diet—high in fat, low in carbohydrates, moderate in protein—delivered through a 14-week supervised outpatient program. What makes this work remarkable is not just that patients tolerated the diet, but what happened to the psychological symptoms that make anorexia so devastating. Even after people regain weight through conventional treatment, they often remain trapped by intense fear of eating, obsessive thoughts about shape, and body dissatisfaction that drives relapse rates alarmingly high. This study tested whether a metabolic intervention could address those underlying brain issues directly.
The results are striking. Of 22 enrolled participants, 18 completed the full 14-week program. By the end, 72 percent of those completers had reached the recovered range on eating disorder assessment scales—meaning they no longer met diagnostic criteria for anorexia nervosa. All participants showed measurable improvements in depression scores, with 72 percent entering the normal range on the Beck Depression Inventory. Critically, no significant weight loss occurred during the program, addressing one of the major clinical sensitivities around dietary interventions in this population.
Frank grounded the work in emerging neuroscience. "Growing evidence links anorexia nervosa to neurometabolic dysfunction," he explained, "and we are hopeful that direct metabolic intervention can regulate neural function and address the psychological symptoms patients experience." The ketogenic approach, already standard in epilepsy care, targets the brain's fundamental energy metabolism rather than simply managing food intake—a conceptual shift that reflects decades of neuroscientific progress.
The study's human foundation runs equally deep. Co-author Barbara Scolnick, an internal medicine physician in Massachusetts, has spent a decade pursuing this research driven by personal stakes: her niece, Caroline Beckwith, struggled with anorexia nervosa for 15 years before achieving remission through ketogenic therapy combined with other interventions. "This study highlights the promise of dietary interventions that target normalizing underlying neurometabolic function for even the most intractable psychiatric conditions like anorexia nervosa," said Jan Ellison Baszucki, whose organization funded the work.
The researchers emphasize that this is proof of concept from a pilot trial, not a cure-all. Yet for people who have exhausted standard treatments, for families watching their loved ones decline despite conventional care, and for clinicians seeking new tools against an illness with one of psychiatry's highest mortality rates, these preliminary findings suggest a genuinely promising direction. The next phase will be larger, controlled trials—but for the first time in years, there is evidence that the brain's own metabolism might hold answers to one of medicine's most stubborn riddles.